

PLENARY SESSIONS	PARALLEL SESSIONS	NETWORKING EVENT	ACADEMY
INDUSTRY SUPPORTED SESSION Not Included in the Main Event CME / CPD Credit	PRE-CONGRESS COURSES		

14th International Congress on Autoimmunity Program

Friday, 17 May 2024

	HALL A	HALL B	HALL C
09:00 - 12:00			<p>PRE-CONGRESS WORKSHOP</p> <p>Ultrasound in autoimmune rheumatic diseases</p> <p>Musculoskeletal ultrasound the ultimate differential diagnostic tool</p> <p>Chairs: Carlo Perricone, Italy, Alexandra Balbir-Gurman, Israel, Alojzija Hocevar, Slovenia</p> <p>Introduction (5 minutes)</p> <p>Carlo Perricone, Alexandra Balbir-Gurman, Alojzija Hocevar</p> <p>Pre-test.</p> <p>Quiz test on elementary pathological lesions</p> <p>Carlo Perricone (10 min)</p> <p>Inflammatory arthritis or osteoarthritis?</p> <p>Alexandra Balbir-Gurman (20 min)</p> <p>Crystal arthropathies</p> <p>Carlo Perricone (20 min)</p> <p>Connective tissue diseases, salivary glands and giant cell arteritis</p> <p>Alojzija Hocevar (20 min)</p> <p>Discussion (15 min)</p> <p>Coffee Break (15 min)</p> <p>Live demo on patients:</p> <p>20 min on osteoarthritis</p> <p>Carlo Perricone</p> <p>20 min on RA</p> <p>Alexandra Balbir-Gurman</p> <p>20 min on CTD (salivary glands)</p> <p>Alojzija Hocevar</p> <p>Post-test.</p> <p>Quiz test on elementary pathological lesions (10 min)</p> <p>Carlo Perricone</p>
12:15 - 17:15		<p>ACADEMY OF AUTOIMMUNITY</p> <p>Autoimmunity up-to date</p> <p>12:15 - 12:45 Autoimmunity vs autoinflammation: same or different? Zoltán Szekanecz, Hungary</p> <p>12:45 - 13:15 Regulatory T cells and Autoimmunity. Mitesh Dwivedi, India</p> <p>13:15 - 13:45 The significance of cytokines in autoimmune diseases. Dimitrios Bogdanos, Greece</p> <p align="center">SHORT BREAK 13:45 - 14:00</p> <p>14:00 - 14:30 Primary biliary cholangitis (PBC)-a classical autoimmune disease. Zsigmond Ehud, Israel</p> <p>14:30 - 15:00 Thyroid autoimmunity in other autoimmune diseases. Alessandro Antonelli, Italy</p> <p align="center">Coffee BREAK 15:00 - 15:15</p> <p>15:15 - 15:45 Comorbidities in autoimmune diseases - state of the art. Lessons learnt from big data analyses. Amital Howard, Israel</p> <p>15:45 - 16:15 IVIG as pancea in autoimmune diseases. Maria Giovanna Danieli, Italy</p> <p>16:15-16:45 Skin Autoimmune Diseases Razzaque Ahmed, USA</p> <p>16:45- 17:15 Prediction in Autoimmunity Luis E. Andrade, Brazil</p>	
17:15-17:45	SHORT BREAK		
17:45-19:30	OPENING CEREMONY & WELCOME RECEPTION Ceremony of Lifetime Contribution to Autoimmunity Awards		

Saturday, 18 May 2024

	HALL A	HALL B	HALL C
08:00 – 10:00 (2 hours)	<p>PLENARY 1 Chairs: Tadej Avcin, Slovenia, Andrea Doria, Italy, Howard Amital, Israel 1. Uveitis in autoimmune diseases - why the uvea is so prevalently involved. Vicktoria Vishnevskia-Dal, Israel 30 min 2. What's still unresolved in Hughes Syndrome /Anti phospholipid syndrome. Graham Hughes, UK 30 min 3. Genetic predisposition to autoimmunity and autoinflammation. Bodo Grimbacher 30 min ----- Challenge the Expert Chairs: Yehuda Shoenfeld, Christopher Edwards, Pier Luigi Meroni Experts: Iris Eshed, Radiology, Israel 15 min 1. CT vs. MRI. Who needs CT when there is MRI? Is there a future for CT imaging? 2. Diffuse idiopathic skeletal hyperostosis, is it an inflammatory disease? 3. Is there a difference between SAPHO (sacroiliitis, Acne Pustulosis, Hyperostosis, Osteitis) and CRMO (chronic relapsing multifocal osteomyelitis)? Dennis McGonagle, Rheumatology, UK 15 min 1. Why doesn't Interleukin-23 blockade work in Ankylosing Spondylitis 2. What is the difference between Ankylosing Spondylitis and axial Psoriatic Arthritis in terms of pathogenesis 3. Will Faecal microbiotal transplants revolution Spondyloarthritis and</p>		
10:00 – 10:30 (30 min)	<p>COFFEE BREAK, EXHIBITION, POSTER VIEWING New Book signing session 1 (10:05-10:25, Exhibition area) 'Autoimmunity, COVID-19, Post-COVID19 Syndrome and COVID-19 Vaccination' Participants: Yehuda Shoenfeld, Arad Dotan</p>		
10:30 – 12:00 (1,5 hour)	<p>PS01 APS: What's new in antiphospholipid syndrome? Chair 1 Graham Hughes, UK Chair 2 Savino Sciascia, Italy Chair 3 Sonja Praprotnik, Slovenia 1. New classification criteria for the antiphospholipid syndrome. Ricard Cervera, Spain 15 min 2. Do the last classification criteria change our routine approach to Anti Phospholipid Syndrome? Pier Luigi Meroni 15 min 3. Time to treat to target in APS. Savino Sciascia, Italy 15 min 4. Challenges in pediatric antiphospholipid syndrome. Tadej Avcin, Slovenia 15 min 5. Implementation of the new ACR/EULAR classification criteria for antiphospholipid syndrome in clinical practice. Saša Čučnik, Slovenia 15 min 6. Abstract ID 378 INTEGRATING ABZGPI-D1ANTIBODIES INTO THE CLINICAL PRACTICE: AN ITALIAN MULTI-CENTER EXPERIENCE, Maria Infantino 15 min</p>	<p>PS02 COVID-19, Post COVID Syndrome and Autoimmunity Chair 1 Carmen Scheibenbogen, Germany Chair 2 Natalia Gavrilova, Russia Chair 3 Zaiga Nora-Krūkle, Latvia 1. Myositis in the COVID-19 Era-Mere coincidence. Dennis McGonagle, UK 15 min 2. COVID-19, Post COVID syndrome, "ME/CFS" Vaccines and Autoimmune Adverse Effects. Carmen Scheibenbogen, Germany 15 min 3. Severity of neurological long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors - single center experience. Nina Babel, Germany 15 min 4. New Onset Autoimmune Diseases after the Sputnik Vaccine. Olga Vera-Lastra, Mexico 15 min 5. IVIG as a treatment option for the post-COVID-19 condition. Personal experience. Natalia Gavrilova, Russia 15 min 6. ASIA as a result of suspected post-vaccinal activation of latent infections Lucija</p>	<p>PS03 Chimeric antigen receptor (CAR) T-cell and novel therapies in autoimmune diseases Chair 1 Sylviane Muller, France Chair 2 Luis E. Andrade, Brazil Chair 3 Doron Rimar, Israel Session dedicated in memory of Prof. Alan Wiik 1. Use of Chimeric Antigen Receptors CART T in SYTEMIC LUPUS Dominique Farge, France 15 min 2. Cell therapy approaches for autoimmune diseases. Luis E. Andrade, Brazil 15 min 3. Novel Therapy Cannabis in Autoimmunity. Howard Amital, Israel 15 min 4. How therapeutic peptides work in autoimmune diseases: P140 peptide corrects failures in secondary lymphoid organs with an impact on remote tissues. Sylviane Muller, France 15 min 5. Glycan as new immunomodulatory targets in SAIDs. Antonio Marinho, Portugal 15 min 6. Predicting treatment response according to RNA gene expression in systemic sclerosis, from bench to bedside. Doron Rimar, Israel 15 min</p>
12:00 – 14:00 (2 hours)	<p>INDUSTRY SUPPORTED SESSION 12:15 - 13:45 NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT</p>	<p>LUNCH BREAK, EXHIBITION, ORAL DISCUSSIONS, E-POSTER VIEWING</p>	<p>INDUSTRY SUPPORTED SESSION 12:15 - 13:45 NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT</p>
14:00 – 15:30 (1,5 hour)	<p>PS04 LUPUS - 2025 Chair 1 Mentago Li, China Chair 2 Luís Inês, Portugal Chair 3 Mariele Gatto, Italy 1. Belimumab vs. Anifrolumab in SLE: which drug in which patient? Andrea Doria, Italy 15 min 2. Challenges of systemic lupus erythematosus associated pulmonary arterial hypertension. Mentago Li, China 15 min 3. Flares in SLE: How to predict and measure in daily clinical practice? Luís Inês, Portugal 15 min 4. Immune complex analyses in systemic lupus erythematosus. Johan Rönnelid, Sweden 15 min 5. Defective lysosomes and lysosomal autophagy in lupus. Sylviane Muller, France 15 min 6. The Digital Patient Pathway in Autoimmune Diseases , Laurent Arnaud, France 15 min</p>	<p>PS05 Pregnancy and Autoimmunity Chair 1 Angela Tincani, Italy Chair 2 Natasa Toplak, Slovenia Chair 3 Caterina De Carolis, Italy 1. The joints in the pregnant lady. Iris Eshed, Israel 15 min 2. Pregnancy and rare systemic autoimmune diseases. Marta Mosca, Italy 15 min 3. Gender medicine in autoimmunity: from bench to bedside and more Roberta Gualtierotti, Italy 15 min 4. Thyroid, autoimmune diseases, recurrent spontaneous abortion and RAFS. Caterina De Carolis, Italy 15 min 5. Abstract ID 267 ASSESSMENT OF OVARIAN DYSFUNCTION IN ADOLESCENT FEMALE PATIENTS WITH SEVERE RHEUMATIC DISEASE RECEIVING CYCLOPHOSAMIDE Cansu Ayten Tatar, 15 min 6. Abstract ID 1082 SELECTIVE SUPPRESSION OF PATHOGENIC B LYMPHOCYTES FROM HASHIMOTO'S THYROIDITIS PATIENTS BY CHIMERIC PROTIEIN MOLECULES Andrey Tchorbanov 15 min</p>	<p>PS06 Systemic Sclerosis, Psoriasis and Spondyloarthritis Chair 1 Abdulla Watad, Israel Chair 2 Dennis McGonagle, UK Chair 3 Alexandra Balbir, Israel 1. Systemic sclerosis: from pathophysiology to novel therapeutic approaches. Katja Lakota, Slovenia 15 min 2. Natural history of systemic sclerosis: a 15-years single-center experience. Dimitrios Bogdanos, Greece 15 min 3. Connective tissue diseases associated PAH. Luc Mouthon, France 15 min 4. Complete resolution of gastric antral vascular ectasia in systemic sclerosis after autologous stem cell transplantation - a case series with long term results. Doron Rimar, Israel 15 min 5. Abstract ID 30 CARDIOVASCULAR OUTCOMES OF SYSTEMIC TREATMENTS IN PSORIASIS AND PSORIATIC ARTHRITIS: A COMPARATIVE ANALYSIS OF BIOLOGICAL AGENTS Arad Dotan, (Howard Amital) 15 min 6. Abstract ID 39 A MACHINE LEARNING TOOL FOR THE EARLY IDENTIFICATION OF UNDIAGNOSED PSORIATIC ARTHRITIS PATIENTS. IS IT POSSIBLE? Jonathan Shapiro 15 min</p>

15:30 – 15:45 (15 min)	SHORT BREAK		
15:45 – 16:45 (1 hour)	<p>PS07 Mechanisms in Autoimmunity (Part 1) Session dedicated in memory of Prof. Noel Rose Chair 1 George Wick, Austria Chair 2 Ferdinando Nicoletti, Italy Chair 3 Dimitrios Bogdanos, Greece</p> <p>1. Abstract ID 1095 SMALL FIBER NEUROPATHY IN MULTIPLE SCLEROSIS PATIENTS Daniela Zohar, Israel 10 min</p> <p>2. Triggering of Autoimmunity by Mechanical Stress. George Wick, Austria 10 min</p> <p>3. Galectins in autoimmune diseases friends or foes? Ferdinando Nicoletti, Italy 10 min</p> <p>4. Vitamin D in Autoimmunity. Ifigania Kostoglou–Athanasidou, Greece 10 min</p> <p>5. RA and type 2 diabetes: the role of the metabolic inflammation. Roberto Giacomelli, Italy 10 min</p> <p>6. The Use of Advanced Infrared Spectroscopy for Diagnosis of Rheumatic Disorders (Fibromyalgia and Rheumatoid Arthritis). Boris Gilburd, Israel 10 min</p>	<p>DEBATE 01 Glucocorticoids in the Management of RA Chairs: Yehuda Shoenfeld, Israel, Johan Rönnelid, Sweden</p> <p>Introduction Yehuda Shoenfeld, Israel, Johan Rönnelid, Sweden 5 min</p> <p>Yes: Maurizio Cutolo, Italy 15 min</p> <p>No: György Nagy, Hungary 15 min</p> <p>Rebuttal 5 min</p> <p>Maurizio Cutolo, Italy</p> <p>Rebuttal 5 min</p> <p>György Nagy, Hungary</p> <p>Discussion 15 min</p>	<p>PS08 Vasculitis - update Chair 1 Gleb Slobodin, Israel Chair 2 Alojzija Hocevar, Slovenia Chair 3 Jan Damoiseaux, The Netherlands</p> <p>1. Innate immunity in ANCA-associated vasculitis. Jan Damoiseaux, The Netherlands 10 min</p> <p>2. CNS vasculitis - update. Gisele Zandman-Goddard, Israel 10 min</p> <p>3. Adult IgA vasculitis. Alojzija Hocevar, Slovenia 10 min</p> <p>4. Polymyalgia rheumatica (PMR) or late onset PMR-like RA - a diagnostic conundrum. Gleb Slobodin, Israel 10 min</p> <p>5. Predictors of remission and flare in patients with polymyalgia rheumatica. Carlo Perricone, Italy 10 min</p> <p>6. Pathways deregulated in giant cell arteritis by gene expression profiling in temporal artery biopsies. Stefania Croci, Italy 10 min</p>
16:45 – 17:15 (30 min)	COFFEE BREAK, EXHIBITION, POSTER VIEWING		
17:15 – 18:30 (1 hour 15 min)	<p>PANEL DISCUSSION 01. Hippocrates versus ChatGPT Discussants: Howard Amital, Israel, Dimitrios Bogdanos, Greece and Antonio Lamas, Portugal</p> <p>How to employ ChatGPT in Medicine and Autoimmunity Yoad Dvir, Israel 15 min</p> <p>Case 1: Diagnostic dilemma Howard Amital, Israel 20 min</p> <p>Case 2: Therapeutic dilemma Dimitrios Bogdanos, Greece 20 min</p> <p>3] HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: ARTIFICIAL INTELLIGENCE AND ITS ROLE IN AIDING DIAGNOSIS Antonio Lamas, Portugal - 20 min</p>	<p>DEBATE 02 What Is the Best Instrument To Measure Disease Activity in SLE? Chair: Andrea Doria, Italy</p> <p>Introduction Andrea Doria, Italy 5 min</p> <p>BILAG: Edward Vital, UK 15 min</p> <p>SLE-DAS: Luís Inês, Portugal 15 min</p> <p>Rebuttal Edward Vital, UK 10 min</p> <p>Rebuttal Luís Inês, Portugal 10 min</p> <p>Discussion 20 min</p>	<p>PS09 Sjögren syndrome and novel therapies in autoimmunity Chair 1 Roberto Gerli, Italy Chair 2 Athanasios Tzioufas, Greece Chair 3 Piercarlo Sarzi-Puttini, Italy</p> <p>1. Sjögren's syndrome towards stratified Medicine. Athanasios Tzioufas, Greece 15 min</p> <p>2. Epidemiology of Sjögren syndrome Roberto Gerli, Italy 15 min</p> <p>3. Accrual damage in Sjogren Syndrome. Roberto Giacomelli, Italy 15 min</p> <p>4. Mixed connective tissue diseases: classification criteria, clinical presentation and prognosis. Luc Mouthon, France 15 min</p> <p>5. Abstract ID 681 ANTI-ROS2 ANTIBODIES AND DISEASE SEVERITY IN PATIENTS WITH SJÖGREN'S DISEASE. Cristian Iperi 7 min</p> <p>6. Abstract ID 648 ADMINISTRATION OF A NOVEL IMMUNE CHECKPOINT MOLECULE TAPBPL AMELIORATES AUTOIMMUNE DISEASES IN MICE Lajun Lai, 7 min</p>
19:15	Off Site: Talk with the Professors		

Sunday, 19 May 2024

	HALL A	HALL B	HALL C
08:00 – 10:00	<p>PLENARY 2 Chairs: Koike Takao, Japan, Saša Čučnik, Slovenia, Dario Roccatello, Italy 1. New paradigms in the management of SLE. Andrea Doria, Italy 30 min 2. Why we develop Autoimmune diseases? Yehuda Shoenfeld, Israel 30 min 3. Daratumumab monotherapy for refractory lupus nephritis. Dario Roccatello, Italy 30 min</p> <p>----- Challenge the Expert Chairs: Yehuda Shoenfeld, Christopher Edwards Experts: Xavier Bossuyt 15 min</p> <p>1. How can reporting of autoantibody test results be improved? 2. Can we reliably measure autoantibodies that recognize conformational epitopes?</p> <p>3. Can the impact of autoantibodies in diagnostic criteria be upgraded? Pier Luigi Meroni 15 min</p> <p>1. Is the old statement 'one autoantibody/one disease' still satisfactory in 2024? 2. Can we use the new diagnostic platforms for assessing the last classification criteria for autoimmune diseases? 3. Can we look at an antiphospholipid panel for improving our diagnostic/prognostic power in APS?</p>		
10:00 – 10:30	COFFEE BREAK, EXHIBITION, POSTER VIEWING, New Book signing session 2 (10:05-10:25, Exhibition area) 'Infection and Autoimmunity' Participants: Prof. Yehuda Shoenfeld, Prof. Naim Mahroum		
10:30 – 12:00	<p>PS10 Infections and Autoimmunity Chair 1 Carlos Vasconcelos, Portugal Chair 2 Naim Mahroum, Turkey Chair 3 Savino Sciascia, Italy</p> <p>1. Infection and Autoimmunity - concept and history, the pandemic of COVID-19. Naim Mahroum, Turkey 15 min 2. Viral-induced networks and their link with the development of "neglected autoimmune diseases" Otávio Marques, Brazil 15 min 3. Post infectious syndromes: spectrum and autoimmune mechanisms Carmen Scheibenbogen, Germany 15 min 4. Serious Infections in Autoimmune disease patients: experience of a single center cohort. Carlos Vasconcelos, Portugal 15 min 5. The unique combination of gut microbiome and viral infection in FM patients Zaiga Nora-Krūkle, Latvia 15 min 6. Adaptive immunity in COVID-19 – two sides of the coin Nina Babel, Germany 15 min</p>	<p>PS11 Autoimmune Syndrome Induced by Adjuvants (Shoenfeld's Syndrome) - Dedicated to the Late Prof LUIS JARA Chair 1 Jan Willem Cohen Tervaert, Canada Chair 2 Olga Vera-Lastra, Mexico Chair 3 Boris Gilburd, Israel</p> <p>1. ASIA (Shoenfeld's syndrome) due to implants: a hype or a real phenomenon? Jan Willem Cohen Tervaert, Canada 15 min 2. Hyperprolactinemia in ASIA after mineral oil injection and silicone breast implants. Olga Vera-Lastra, Mexico 15 min 3. ASIA and silicone Gustavo Emilio Schenone, Argentina 15 min 4. Tattoo and Autoimmunity. Amir Tanay, Israel 15 min 5. Is vaccination in children with immune mediated diseases safe and immunogenic? Natasa Toplak, Slovenia 15 min 6. Exploring the exposome's influence on vaccination effectiveness. Pedro Bastos, Sweden 15 min</p>	<p>PS12 Autoimmunity in the Central Nervous System Chair 1 Ron Milo, Israel Chair 2 Manuel Martinez-Lavin, Mexico Chair 3 Daniela Zohar, Israel</p> <p>1. Better understanding the underlying mechanism of fibromyalgia syndrome using circulating extracellular vesicles. Gilad Halpert, Israel 15 min 2. Fibromyalgia : neuroinflammation or autoimmunity? Piercarlo Sarzi-Puttini, Italy 15 min 3. The different clinical manifestations of small fiber neuropathy. Manuel Martinez-Lavin, Mexico 15 min 4. New B cell-targeted therapies for multiple sclerosis. Ron Milo, Israel 15 min 5. The nervous system in rheumatoid arthritis. Christopher Edwards, UK 15 min 6. Abstract ID 967 MECHANISMS OF PAIN MODULATION BY JAK INHIBITION: UPADACITINIB REGULATES PAIN-RELATED PATHWAYS AND BDNF EXPRESSION IN MICROGLIAL CELLS Luca Navarini, Italy 15 min</p>
12:00 – 14:00	INDUSTRY SUPPORTED SESSION 12:15 - 13:45 NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT	LUNCH BREAK, EXHIBITION, ORAL DISCUSSIONS, E-POSTER VIEWING, New Book signing session 3 (12:10 - 13:10, Exhibition area) 'Adjuvants and Autoimmunity/ASIA Syndrome' Participants: Prof. Yehuda Shoenfeld, Prof. Abdulla Watad	

14:00 – 15:30	<p>PS13 Rheumatoid Arthritis and Myositis (Muscles) Chair 1 Christopher Edwards, UK Chair 2 Gleb Slobodin, Israel Chair 3 Olga Vera-Lastra, Mexico</p> <p>1. Ways to prevent difficult-to-treat RA. Gleb Slobodin, Israel 15 min 2. Efficacy and safety of JAKI for the treatment of RA in real-life. Carlo Perricone, Italy 15 min 3. Inflammatory myopathies and ILD. Sonja Praprotnik, Slovenia 15 min 4. Abstract ID 510 From fat to muscle- an unusual type of myositis - a case report and literature review. Milena Tocut, Israel 7 min 5. Correct nutrition as immunomodulatory co-therapy in rheumatoid arthritis. Maurizio Cutolo, Italy 15 min 6. Abstract ID 230 FUNCTIONAL CONNECTIVITY ASSOCIATED WITH RESPONSE TO BIOLOGICS IN RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS Yuichiro Fujieda 15 min 7. Abstract ID 970 ROLE OF SCLERODERMA/MYOSITIS-RELATED AUTOANTIBODIES DETECTED BY IMMUNOBLOT TO THE DIAGNOSIS OF SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES IN 410 PATIENTS FROM A SINGLE REFERRAL CENTER Juan Laura-Ventura 7 min</p>	<p>PS14 Therapeutic Challenges in Autoimmunity Chair 1 Martin Aringer, Germany Chair 2 Gellerman Gary, Israel Chair 3 Doron Rimar, Israel</p> <p>1. Helminth derivative to treat autoimmunity. Miri Blank, Israel 15 min 2. News on Janus kinase (Jak) function and Jak inhibition in SLE. Martin Aringer, Germany 15 min 3. Autologous stem cell transplantation versus upfront combination therapy of rituximab and mycophenolate mofetil for progressive diffuse systemic sclerosis - 2 year outcomes. Doron Rimar, Israel 15 min 4. Antibody-driven photodynamic and sonodynamic therapies: a look into the future of targeted medicine. Gary Gellerman, Israel 15 min 5. Functional consequences of immunological checkpoint inhibitor therapies on lymphocytes. Ulrich Sack, Germany 15 min 6. Therapeutic Dilemmas: Three Short Cases Employing Patient-Centered Research - Antiphospholipid antibodies and Transverse Myelitis, JC virus screening and Rituximab, Necrotizing Myositis. Or Degany, Israel and Mark Volevich, Israel 15 min</p>	<p>PS15 EASI Session: The new APS classification criteria: implications in clinical practice Chair 1 Nicola Bizarro, Italy Chair 2 Marcos Hoyos, Spain</p> <p>1. Assessment of the clinical domain within the new APS classification criteria Denis Wahl, France 20 min 2. Laboratory classification criteria for APS are not the same as diagnostic laboratory criteria for APS Katrien Devreese, Belgium 20 min 3. The impact of the new APS classification criteria on pregnancy morbidity. Savino Sciascia, Italy 20 min 4. Panel discussion, Lieve Van Hoovels, Belgium 30 min</p>
15:30 – 15:45	SHORT BREAK		
15:45 – 16:45	<p>PS16 Big data, Prediction, Monitoring and Prevention Chair 1 Gisele Zandman-Goddard, Israel Chair 2 Matthias Schneider, Germany Chair 3 Uri Kapilov (Israel)</p> <p>1. Standardized core data sets. Matthias Schneider, Germany 10 min 2. Precision medicine in Lupus. Gisele Zandman-Goddard, Israel 10 min 3. Predictors of severe autoimmune haemolytic anaemia and severe thrombocytopenia in SLE. Bernardo Pons-Estel, Argentina 10 min 4. Autoantibodies and Precision Medicine. Luis E. Andrade, Brazil 10 min 5. Abs against the chemokine receptor CXCR3 as predictor for mortality in a population-based study. Hanna Grasshoff, Germany 10 min 6. Big Data in psoriasis. Howard Amital, Israel 10 min</p>	<p>DEBATE 03 Might Maintenance Therapy Be Discontinued Once Clinical Remission Is Achieved in ANCA-Associated Vasculitis Chair: Ricard Cervera, Spain, Piero Ruscitti, Italy</p> <p>Introduction Ricard Cervera, Spain, Piero Ruscitti, Italy 5 min No: Carlo Salvarani, Italy 15 min Yes: Dario Roccatello, Italy 15 min Rebuttal Carlo Salvarani, Italy 5 min Rebuttal Dario Roccatello, Italy 5 min Discussion 15 min</p>	<p>PS17 Autoantibodies (ABS) - Prediction, Pathogenic and Prevention Chair 1 Pier Luigi Meroni, Italy Chair 2 Michael Mahler, USA Chair 3 Xavier Bossuyt, Belgium</p> <p>1. Much more than anti-dsDNA antibodies for lupus nephritis. Pier Luigi Meroni, Italy 10 min 2. Autoimmunity, Immunodeficiency and Autoinflammation in a cohort of patients from a clinical immunology unit. Carlos Vasconcelos, Portugal 10 min 3. The stratification of autoimmune patients for personalized therapy: importance of flow cytometry. Christophe Jamin, France 10 min 4. Abstract ID 957 TUFTSIN-PHOSPHOPRYLCHOLINE, BASED ON HELMINTH DERIVATIVE, DECREASED IL-8 EXPRESSION BY HUMAN ENDOTHELIAL CELLS AND TEMPORAL ARTERY BIOPSIES FROM GIANT CELL ARTERITIS PATIENTS Stefania Croci, 10 min 5. Abstract ID 692 TRANSCRIPTOMIC PROFILING REVEALS NOVEL INSIGHTS INTO THE CELLULAR PROTECTIVE FUNCTIONS OF THE DFS70/LEDGF NUCLEAR AUTOANTIGEN Carlos Casiano, 10 min 6. Abstract ID 221 REMISSION IN LUPUS IS AFFECTED BY COMORBIDITIES Abihal Lucas Hernández 10 min</p>
16:45 – 17:15	COFFEE BREAK, EXHIBITION, POSTER VIEWING		
17:15 – 18:30	<p>PANEL DISCUSSION 02 - Difficult cases in Autoimmunity Panel: Carlo Salvarani, Italy, Razzaque Ahmed, USA, Carlo Perricone Italy, Savino Sciascia, Italy</p> <p>1. Case of overlapping EGPA/GPA Carlo Perricone, Italy 15 min Discussion 10 min Moderator; Carlo Salvarani, Italy 2. Case of alopecia universalis which improved at 1 month of treatment with JAK1 inhibitor upadacitinib Carlo Perricone, Italy 15 min Discussion 10 min Moderator; Razzaque Ahmed, USA 3. Case on LUPUS/C-APS Ricard Cervera, Spain 15 min Discussion 10 min Moderator; Savino Sciascia, Italy</p>	<p>PS18 Cytokines and Autoimmunity Chair 1 Pierre Miossec, France Chair 2 Luca Cantarini, Italy Chair 3 Oliver Distler, Switzerland</p> <p>1. IL-17, 25 years later. Pierre Miossec, France 15 min 2. IL-1beta inhibition in Adult onset Still's disease. Luca Cantarini, Italy 15 min 3. IL-6, the choroid plexus, and the pathogenesis of neuropsychiatric lupus. Chaim Putterman, Israel 15 min 4. The emerging role of macrophage migration inhibitory family of cytokines in autoimmune diseases. From pathogenesis to new treatments? Ferdinando Nicoletti, Italy 15 min 5. Abstract 894 A HUNDREDFOLD GREATER INDUCTION OF IL-23 FROM AXIAL ENTHESES BONE COMPARED TO PERIPHERAL ENTHESES AS AN EXPLANATION FOR IL-23 BLOCKADE FAILURE IN ANKYLOSING SPONDYLITIS BUT NOT PERIPHERAL PSORIATIC ARTHRITIS Paula David 15 min.</p>	<p>PS19 Systemic Autoimmunity, Liver and Gastrointestinal Chair 1 Aaron Lerner, Israel Chair 2 Roberta Gualtierotti, Italy Chair 3 Zigmund Ehud, Israel</p> <p>1. Cross-Reactivity and sequence similarity between microbial transglutaminase and human antigens: expanding the exposome of autoimmune diseases. Aaron Lerner, Israel 15 min 2. Systemic treatment for alopecia areata. Gasper Markelj, Slovenia 15 min 3. Abstract ID 216 CHOLANGITIS INDUCED BY IMMUNE CHECKPOINT INHIBITORS: ANALYSIS OF PHARMACOVIGILANCE DATA Alexandre Maria, 10 min 4. Abstract ID 433 SERUM ANTICARDIOLIPIN ANTIBODIES AND ENDOTHELIN-1 AS MARKERS OF PORTAL HYPERTENSION IN PRIMARY BILIARY CHOLANGITIS Alicja Bauer, 10 min 5. Abstract ID 332 HUMAN ANTIMICROBIAL GLYCOPROTEIN-2 EXPRESSED IN BRUNNER GLANDS – A PUTATIVE AUTOIMMUNE TARGET OF CROHN'S AND COELIAC DISEASE Dirk Roggenbuck 10 min 6. Abstract ID 754 IL-10-PRODUCING REGULATORY CELLS IMPACT ON CELIAC DISEASE EVOLUTION Carmen Gianfrani 10 min 7. Abstract ID 964 UNVEILING POTENTIAL BIOMARKERS FOR INFLAMMATORY BOWEL DISEASES (IBDS) AND COLORECTAL CARCINOMA (CRC) DIAGNOSIS THROUGH SALIVA PROTEOMIC PROFILING Nicole Contran 5 min</p>

Monday, 20 May 2024

	HALL A	HALL B	HALL C
08:00 – 10:00	<p>PLENARY 3 Chairs: Angela Tincani, Italy, Christopher Edwards, UK, TBA 1. MAI award winners 2024, 8 minutes each</p> <p>2. Prediction and prevention of autoimmunity (Using example of Rheumatoid Arthritis, Prediction Models, Review of status of prevention trials). Michael Mahler, USA 30 min</p> <p>3. Paraneoplastic Autoimmune Laminin-332 Syndrome (PALS). Razzaque Ahmed, USA 30 min ----- Challenge the Expert Chairs: Yehuda Shoenfeld, Christopher Edwards Experts: Alessandro Antonelli, Italy 15 min</p> <p>1. Which is the prevalence of systemic autoimmune disorders in patients with autoimmune thyroid diseases, and which is the impact on the health of these patients? 2. Which are the new therapies for Graves' ophthalmopathy, and which is the impact on the disease? 3. Which is the impact of Covid-19 infection in patients with thyroid autoimmunity? Andrea Doria, Italy 15 min</p> <p>1. Is it common to achieve the T2T goals in SLE patients? 2. Why should we use biologics early in SLE patients? 3. Can we withdraw low-dose-glucocorticoid in remitted SLE patients?</p>		
10:00 – 10:30	COFFEE BREAK, EXHIBITION, POSTER VIEWING		
10:30 – 12:00	<p>PS20 Novel Autoimmune Diseases Chair 1 Ora Showman, Israel Chair 2 Ivica Lazurova, Slovakia Chair 3 Michael Ehrenfeld, Israel</p> <p>1. Hypocryoglobulinaemia: a new entity? Dario Roccatello, Italy 15 min 2. Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications. Piero Ruscitti, Italy 15 min 3. An update on CPPD diagnosis and management. Ora Showman, Israel 15 min 4. What's immune in ankylosing spondylitis? (or difficult cases) Abdulla Watad, Israel 15 min 5. Acquired hemophilia: a too often overlooked autoimmune disease. Roberta Gualtierotti, Italy 15 min 6. Abstract ID 263 AUTOIMMUNITY AND ENDOMETRIOSIS: POTENTIAL RELEVANCE OF A NOVEL IMMUNOMODULATING COMPOUND Michael Agrez, 15 min</p>	<p>PS21 Systemic Sclerosis Chair 1 Alexandra Balbir-Gurman, Israel Chair 2 Oliver Distler, Switzerland Chair 3 Yaniv Sherer, Israel</p> <p>1. When to start or escalate treatment in SSC-ILD. Oliver Distler, Switzerland 30 min 2. Abstract ID 487 CHRONIC FATIGUE AS A MARKER OF MITOCHONDRIAL DYSFUNCTION, HYPOXIC STRESS AND VASCULAR REMODELLING IN EARLY SYSTEMIC SCLEROSIS Charmaine van Eeden 10 min 3. Abstract ID 638 SHAPING MONOCYTE PATHOGENICITY IN SYSTEMIC SCLEROSIS: THE CONVERGENCE OF AT1R AUTOANTIBODIES AND EXTRACELLULAR VESICLES Alexander Hackel 10 min 4. Abstract ID 699 THE ROLE OF CXCL4-L1, THE NON-ALLELIC VARIANT OF CXCL4, IN SYSTEMIC SCLEROSIS Loredana Frasca 10 min 5. Abstract ID 746 ANTIOXIDANT ENZYMES IN SYSTEMIC SCLEROSIS Neža Brezovec 10 min 6. Abstract ID 1021 CONVENTIONAL TYPE 1 DENDRITIC CELLS ARE ESSENTIAL FOR THE DEVELOPMENT OF PRIMARY BILIARY CHOLANGITIS Debby Reuveni 10 min 7. TBA</p>	<p>PS22 Novel Approaches to Handle Autoimmune Diseases Chair 1 Gilad Halpert, Israel Chair 2 Carlo Salvarani, Italy Chair 3 David Naor, Israel</p> <p>1. Modulation of autoimmune diseases by targeting the Nfr2-HO1-CO pathway. Ferdinando Nicoletti, Italy 15 min 2. Acupuncture therapy of Autoimmune diseases – State of the Art. Dorit Gamus, Israel 15 min 3. The potential of autologous patient-derived circulating extracellular vesicles to improve drug delivery in inflammatory rheumatic autoimmune diseases. Gilad Halpert, Israel 15 min 4. What's new in the treatment of large vessel vasculitis. Carlo Salvarani, Italy 15 min 5. Abstract ID 695 NOVEL AUTOANTIGEN PEPTIDE EPITOPES AS THERANOSTIC TARGETS IN INCURABLE AUTOIMMUNE BLISTERING DISEASES. Simon D. Lytton 15 min 6. Abstract ID 308 MTADY 5-MER peptide suppresses lung fibrosis, RA, IBD and MS mouse models and inhibits human fibroblasts biological functions by targeting SAA, which fuels fibrosis David Naor, Israel 15 min</p>
12:00 – 14:00	LUNCH BREAK, EXHIBITION, POSTER VIEWING		INDUSTRY SUPPORTED SESSION 12:15 - 13:45 NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT

14:00 – 15:30	<p>PS23 Pediatric and Autoimmunity Chair 1 Sefi Uziel, Israel Chair 2 Tadej Avcin, Slovenia Chair 3 Angello Ravelli, Italy</p> <p>1. Next generation: what we know of children born to patients with systemic autoimmune diseases. Angela Tincani, Italy 15 min 2. APLA- SLE- TTP- MAS- what is the egg and what is the chicken? Sefi Uziel, Israel 15 min 3. Immune interventions in pre- and early- type 1 diabetes. Tadej Battelino, Slovenia 15 min 4. Autoimmunity in inborn errors of immunity and clinical approaches. Tadej Avcin, Slovenia 15 min 5. Monogenic causes of SLE and related clinical conditions. Alexandre Belot, France 15 min 6. Advances in the management of juvenile idiopathic arthritis. Angelo Ravelli, Italy 15 min</p>	<p>PS24 Mechanisms in Autoimmunity (Part 2) Chair 1 Ferdinando Nicoletti, Italy Chair 2 Marcos López-Hoyos, Spain Chair 3 Christophe Jamin, France</p> <p>1. Abstarct ID 702 EXTRACELLULAR VESICLES IN PATIENTS WITH THROMBOTIC ANTIPHOSPHOLIPID SYNDROME INDICATE ONGOING ENDOTHELIAL AND PLATELET ACTIVATION. Polona Žigon, Slovenia 15 min 2. Auto and allo-immunity in solid organ transplantation. Risk for humoral graft rejection. Marcos López-Hoyos, Spain 15 min 3. Abstract ID 265 TAKING THE AUTOIMMUNE STING OUT OF PD-1 CHECKPOINT INHIBITION TO SUPPRESS CANCER GROWTH Michael Agrez 15 min 4. Abstract ID 309 TYPE 2 NKT CELLS DIRECTED IMMUNE REGULATORY MECHANISM IN LUPUS NEPHRITIS Vipin Kumar 15 min 5. Abstract ID 319 IMMUNE-CHECKPOINT INHIBITION AND AUTOIMMUNITY: YIN AND YANG Zoltan Szekanecz 15 min 6. Abstract ID 643 THE MOLECULAR INTERPLAY BETWEEN THE TRANSCRIPTION FACTORS ETS-2 AND FOXP3 IN EFFECTOR AND REGULATORY CD4+ T-CELLS IS INVOLVED IN THE</p>	<p>PS25 Diagnostics in Autoimmunity Chair 1 Nicola Bizzaro, Italy Chair 2 Torsten Matthias Chair 3 Maria Infantino, Italy</p> <p>1. EULAR/ACR 2019 SLE classification criteria – lessons learned in the first five years. Martin Aringer, Germany 15 min 2. Critical issues in autoantibody tests used as classification criteria for autoimmune diseases. Nicola Bizzaro, Italy 15 min 3. Circulating calprotectin: a marker gaining awareness. Maria Infantino, Italy 15 min 4. Revolutionizing GRD Diagnosis: Novel Epitopes And Multiparametric Diagnostics To Eliminate Unnecessary Biopsies. Torsten Matthias, Germany 15 min 5. Abstract ID 647 IDENTIFICATION OF NOVEL ANTIGENIC TARGETS USING ANTIBODY PROFILING IN SPINAL CORD INJURY PATIENTS Astrid Pues 15 min 6. Autoantibody Standardization Committee: Priorities & Best Practices for Autoantibody Standardization Mark Wener, USA 15 min</p>
SHORT BREAK			
15:45 – 16:45	<p>PS26 Pearls in Autoimmunity 2024 Chair 1 Amir Tanay, Israel Chair 2 Otávio Marques, Brazil Chair 3 Luc Mouthon, France</p> <p>1. COVID-19 vaccine related autoimmune rheumatic diseases. Michael Ehrenfeld, Israel 15 min 2. Allergy and Autoimmunity, revisited "through the looking glass" Amir Tanay, Israel 15 min 4. Is the syndrome of postural orthostatic tachycardia autoimmune ? (results and review) Zora Lazurova, Slovakia 15 min 4. Abstract ID 1104 UNDERSTANDING THE INFECTIOUS ORIGIN OF AUTOIMMUNITY FROM THE SARS-COV-2 PANDEMIC. Bhupesh Prusty, Germany 15 min</p>	<p>PS27 Nutrition and Life Style in Autoimmunity Chair 1 Pedro Bastos, Sweden Chair 2 Vania Borba, Portugal Chair 3 Mohammad Adawi</p> <p>1. Emerging role of Nutrition in the prevention and treatment of autoimmune diseases and immunosenescence. Vania Borba, Portugal 15 min 2. The food additive: microbial transglutaminase is a potential inducer of autoimmune diseases. Aaron Lerner, Israel 15 min 3. Lifestyle triggers of neuroinflammation. Pedro Bastos, Sweden 15 min 4. Abstract ID 292 THE RELATIONSHIP BETWEEN FIBROMYALGIA AND NUTRITION- AN UP TO DATE REVIEW OF THE LITERATURE Mohammad Adawi 15 min</p>	<p>PS28 Thyroid and Endocrine System Chair 1 Alessandro Antonelli, Italy Chair 2 Ifigania Kostoglou–Athanasiou, Greece Chair 3 Roberto Giacomelli, Italy</p> <p>1. Graves' Ophthalmopathy epidemiology, pathogenesis and new therapies. Alessandro Antonelli, Italy 15 min 2. Vitamin D levels in Slovak women with autoimmune thyroid disease. Ivica Lazurova, Slovakia 15 min 3. Thyroid autoimmunity and COVID-19. Ifigania Kostoglou–Athanasiou, Greece 15 min 4. ANTIBODY-MEDIATED RESPONSE TO SARS-COV-2, EBV, HHV-SUPERANTIGENS AND ACTIVIN-A UNDERPINS DIAGNOSIS OF LONG COVID AND ME/CFS Aristo Vojdani, USA 15 min</p>
COFFEE BREAK, EXHIBITION, POSTER VIEWING			
17:15 – 18:30	<p>PS29 Pathogenesis of Autoimmune Condition Chair 1 Stefania Croci, Italy Chair 2 Tadej Battelino, Slovenia Chair 3 Dominique Farge, France</p> <p>1. Update on checkpoint inhibitors induced autoimmunity. Michael Ehrenfeld, Israel 15 min 2. Checkpoint proteins as a gate between autoimmune rheumatic diseases and cancer. Maurizio Cutolo, Italy 15 min 3. Hyperferritinemia as a marker of worse outcome in patients with COVID-19 at hospital admission. Gisele Zandman-Goddard, Israel 15 min 4. Eosinophilic fasciitis: from diagnosis to treatment. Luc Mouthon, France 15 min 5. Abstract ID 687 ANTI-CITRULLINATED HISTONE ANTIBODY CIT-013, A DUAL ACTION THERAPEUTIC FOR NEUTROPHIL EXTRACELLULAR TRAP ASSOCIATED AUTOIMMUNE DISEASES Annemarie Kip, 7 min 6. Abstract ID 1076 ASSESSMENT OF IMMUNE CELL ACTIVATION IN PEMPHIGUS Mateusz Mleczko 7 min</p>	<p>PS30 Kidney and Autoimmunity Chair 1 Chaim Putterman, Israel Chair 2 Sylviane Muller, France Chair 3 Gasper Markelj, Slovenia</p> <p>1. Update on therapy of lupus nephritis with special focus on refractory forms. Dario Roccatello, Italy 15 min 2. Long term renal outcome in a cohort of Portuguese Lupus patients. Carlos Vasconcelos, Portugal 15 min 3. The CD6/ALCAM pathway as a novel biomarker and treatment target in lupus nephritis. Chaim Putterman, Israel 15 min 4. Difficult to treat systemic lupus erythematosus. Marta Mosca, Italy 15 min 5. Is Protocol Biopsy Required in Lupus Nephritis? Mariele Gatto, Italy 15 min</p>	<p>PS31 ICAP Session : Focus on the clinical relevance of the HEp-2 IFA (ANA) test Chair 1 - Luis Andrade, Brazil Chair 2 - Maria Infantino, Italy</p> <p>1. Novel clinically relevant patterns and evolution of the ICAP classification tree Luis Andrade, Brazil, 20 min 2. Practical difficulties in fitting some images into the ICAP classification tree Jan Damoiseaux, Netherlands 20 minutes 3. Multiple, mixed, and composite patterns Luis Andrade, Brazil 15 minutes 4. Frequently Asked Questions for ICAP Maria Infantino, Italy 20 minutes</p>